[go: up one dir, main page]

NO20090175L - Stabile laquinimod sammensetninger - Google Patents

Stabile laquinimod sammensetninger

Info

Publication number
NO20090175L
NO20090175L NO20090175A NO20090175A NO20090175L NO 20090175 L NO20090175 L NO 20090175L NO 20090175 A NO20090175 A NO 20090175A NO 20090175 A NO20090175 A NO 20090175A NO 20090175 L NO20090175 L NO 20090175L
Authority
NO
Norway
Prior art keywords
compositions
laquinimod
stable
stable laquinimod
pharmaceutically acceptable
Prior art date
Application number
NO20090175A
Other languages
English (en)
Other versions
NO342485B1 (no
Inventor
Adrian Gilbert
Shulamit Patashnik
Daniella Licht
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of NO20090175L publication Critical patent/NO20090175L/no
Publication of NO342485B1 publication Critical patent/NO342485B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Composite Materials (AREA)
  • Mechanical Engineering (AREA)

Abstract

Oppfinnelsen vedrører en farmasøytisk sammensetning som omfatter et farmasøytisk akseptabelt salt av N-etyl-N-fenyl-1,2-dihydro-4-hydroksy-5-klor-1-metyl-2-oksoquinolin-3-karboksamid, N-metylglukamin og en farmasøytisk akseptabel bærer.
NO20090175A 2006-06-12 2009-01-12 Stabile laquinimod preparater NO342485B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81324706P 2006-06-12 2006-06-12
PCT/US2007/013721 WO2007146248A2 (en) 2006-06-12 2007-06-12 Stable laquinimod preparations

Publications (2)

Publication Number Publication Date
NO20090175L true NO20090175L (no) 2009-03-11
NO342485B1 NO342485B1 (no) 2018-05-28

Family

ID=38832466

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090175A NO342485B1 (no) 2006-06-12 2009-01-12 Stabile laquinimod preparater

Country Status (28)

Country Link
US (3) US7989473B2 (no)
EP (1) EP2035001B1 (no)
JP (1) JP5226678B2 (no)
KR (4) KR20160013273A (no)
CN (1) CN101466379B (no)
AR (1) AR061348A1 (no)
AT (1) ATE532515T1 (no)
AU (1) AU2007258366B2 (no)
BR (1) BRPI0713694A2 (no)
CA (2) CA2899472C (no)
CY (1) CY1113003T1 (no)
DK (1) DK2035001T3 (no)
EA (1) EA018031B1 (no)
ES (1) ES2377149T3 (no)
HK (1) HK1121971A1 (no)
HR (1) HRP20120093T1 (no)
IL (1) IL195724A (no)
MX (1) MX2008015808A (no)
NO (1) NO342485B1 (no)
NZ (1) NZ573846A (no)
PL (1) PL2035001T3 (no)
PT (1) PT2035001E (no)
RS (1) RS52169B (no)
SI (1) SI2035001T1 (no)
TW (1) TWI400073B (no)
UA (1) UA96449C2 (no)
WO (1) WO2007146248A2 (no)
ZA (1) ZA200810790B (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
RS53666B1 (en) * 2005-10-19 2015-04-30 Teva Pharmaceutical Industries Ltd CRYSTALS OF SODIUM LAKVINIMOD AND THE PROCESS FOR OBTAINING THEM
ZA200810790B (en) 2006-06-12 2010-03-31 Teva Pharma Stable laquinimod preparations
EP2682120B1 (en) * 2007-12-20 2016-08-03 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
ES2633658T3 (es) * 2008-09-03 2017-09-22 Teva Pharmaceutical Industries Ltd. Moduladores 2-oxo-1,2-dihidro-quinolina de la función inmunitaria
DE102010048788A1 (de) 2009-02-13 2011-05-19 Amw Gmbh Transdermales System mit Immunmodulator
DE102009008851A1 (de) 2009-02-13 2010-08-19 Amw Gmbh Transdermales System mit Immunmodulator
EA201270041A1 (ru) 2009-06-19 2012-06-29 Тева Фармасьютикал Индастриз Лтд. Лечение рассеянного склероза лаквинимодом
EP2458992B1 (en) * 2009-07-30 2015-12-16 Teva Pharmaceutical Industries Ltd. Treatment of crohn's disease with laquinimod
PL2467372T3 (pl) 2009-08-10 2017-04-28 Teva Pharmaceutical Industries Ltd. Leczenie zaburzeń związanych z BDNF z zastosowaniem lakwinimodu
DE102010026879A1 (de) 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
PH12012501740A1 (en) * 2010-03-03 2012-11-12 Teva Pharma Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
JP2013521305A (ja) * 2010-03-03 2013-06-10 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドを用いるループス関節炎の治療
US8889661B2 (en) * 2010-03-03 2014-11-18 Teva Pharmaceutical Industries, Ltd. Treatment of lupus nephritis using laquinimod
MX2013000332A (es) * 2010-07-09 2013-02-26 Teva Pharma 5-cloro-4-hidroxi-1-metil-2-oxo-n-fenil-1,2-dihidroquinolina-3-ca rboxamida, sales y usos de la misma.
EP2597954A4 (en) 2010-07-09 2014-01-01 Teva Pharma DEUTERATED N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOCHINOLINE-3-CARBOXAMIDE, SALT THEREOF AND APPLICATIONS THEREOF
EP2648732A4 (en) * 2010-12-07 2014-04-30 Teva Pharma USE OF LAQUINIMOD TO REDUCE TEMPERATURE, IMPROVE FUNCTIONAL STATUS AND IMPROVE LIFE QUALITY IN PATIENTS WITH MULTIPLE SCLEROSIS
CA2843432A1 (en) * 2011-07-28 2013-01-31 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and interferon-beta
JP2014521658A (ja) * 2011-07-28 2014-08-28 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療
EP2766020A4 (en) * 2011-10-12 2015-04-01 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD
EP2811832A4 (en) 2012-02-03 2015-09-23 Teva Pharma USE OF LAQUINIMOD FOR THE TREATMENT OF PATIENTS WITH MORBUS CROHN AFTER FAILED PREVIOUS ANTI-TNF THERAPY
CA2863409A1 (en) 2012-02-16 2013-08-22 Teva Pharmaceutical Industries Ltd. N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof
US20130259856A1 (en) 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
US20130345257A1 (en) * 2012-06-26 2013-12-26 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
AR091706A1 (es) * 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
TW201410243A (zh) * 2012-08-13 2014-03-16 Teva Pharma 用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
TW201410244A (zh) * 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
BR112015010193A2 (pt) * 2012-11-07 2017-07-11 Teva Pharma sais de amina de laquinimod
MX2015010296A (es) * 2013-02-15 2016-05-05 Teva Pharma Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
US20160038435A1 (en) 2013-03-14 2016-02-11 Teva Pharmaceutical Industries Ltd. Transdermal formulations of laquinimod
KR20150143499A (ko) * 2013-03-14 2015-12-23 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드 나트륨의 결정 및 이의 개선된 제조방법
CN105848653A (zh) * 2013-09-27 2016-08-10 梯瓦制药工业有限公司 用于治疗多发性硬化症的拉喹莫德联合治疗
AR098832A1 (es) * 2013-12-20 2016-06-15 Teva Pharma Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
US20160331742A1 (en) * 2014-01-17 2016-11-17 Teva Pharmaceutical Industries, Ltd. Treatment of crohn's disease using low doses of laquinimod
UY36099A (es) 2014-04-29 2016-02-29 Teva Pharma Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad
CN110193014B (zh) * 2019-06-06 2021-05-11 温州医科大学 一种注射用拉喹莫德胶束冻干制剂及制备方法、拉喹莫德注射制剂

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3024257A (en) * 1961-04-10 1962-03-06 Frosst & Co Charles E Stable preparations of alkali metal salts of estrone sulfate
FR2340735A1 (fr) * 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
DE3437232A1 (de) * 1984-10-10 1986-04-17 Mack Chem Pharm Stabilisierte injektionsloesungen von piroxicam
SE8902076D0 (sv) 1989-06-09 1989-06-09 Pharmacia Ab Derivatives of quinoline-3-carboxanilide
HUT60458A (en) 1991-02-01 1992-09-28 Sandoz Ag Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
CH687615A5 (de) * 1994-09-07 1997-01-15 R W Johnson Pharmaceutical Res Tropen-Verpackung.
US5912349A (en) * 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
EE200100660A (et) 1999-06-07 2003-04-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Ravimvorm happe suhtes labiilsete toimeainete jaoks, toimeaine üksus, selle valmistamismeetod ja mikrokerake
SE0002320D0 (sv) 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
PL199781B1 (pl) * 1999-10-25 2008-10-31 Active Biotech Ab Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania
JP2002031610A (ja) 2000-07-14 2002-01-31 Ajinomoto Co Inc 生体分子複合体の界面残基を同定する方法
US6307050B1 (en) * 2000-08-29 2001-10-23 R. T. Alamo Venture I Llc Method of synthesizing flosequinan from 4-fluoroanthranilic acid
US6802422B2 (en) * 2000-12-12 2004-10-12 Multi-Comp, Inc. Sealed blister assembly
US6706733B2 (en) 2001-05-08 2004-03-16 Dainippon Ink And Chemicals, Inc. Quinolinone derivative formulation and its production method
US20030119826A1 (en) * 2001-09-24 2003-06-26 Pharmacia Corporation Neuroprotective treatment methods using selective iNOS inhibitors
SE0201778D0 (sv) * 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) * 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
US6875869B2 (en) * 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US8980870B2 (en) * 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
US7820145B2 (en) * 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
EP1694308A1 (en) * 2003-10-30 2006-08-30 Lupin Ltd. Stable formulations of ace inhibitors and methods for preparation thereof
US8314124B2 (en) * 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
RS53666B1 (en) 2005-10-19 2015-04-30 Teva Pharmaceutical Industries Ltd CRYSTALS OF SODIUM LAKVINIMOD AND THE PROCESS FOR OBTAINING THEM
ZA200810790B (en) 2006-06-12 2010-03-31 Teva Pharma Stable laquinimod preparations
US20080087929A1 (en) * 2006-10-11 2008-04-17 Infineon Technologies Ag Static random access memory with thin oxide capacitor
EP2682120B1 (en) 2007-12-20 2016-08-03 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
ES2633658T3 (es) 2008-09-03 2017-09-22 Teva Pharmaceutical Industries Ltd. Moduladores 2-oxo-1,2-dihidro-quinolina de la función inmunitaria
EA201270041A1 (ru) 2009-06-19 2012-06-29 Тева Фармасьютикал Индастриз Лтд. Лечение рассеянного склероза лаквинимодом
EP2458992B1 (en) 2009-07-30 2015-12-16 Teva Pharmaceutical Industries Ltd. Treatment of crohn's disease with laquinimod
PL2467372T3 (pl) 2009-08-10 2017-04-28 Teva Pharmaceutical Industries Ltd. Leczenie zaburzeń związanych z BDNF z zastosowaniem lakwinimodu
US8889661B2 (en) 2010-03-03 2014-11-18 Teva Pharmaceutical Industries, Ltd. Treatment of lupus nephritis using laquinimod
PH12012501740A1 (en) 2010-03-03 2012-11-12 Teva Pharma Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
JP2013521305A (ja) 2010-03-03 2013-06-10 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドを用いるループス関節炎の治療
MX2013000332A (es) 2010-07-09 2013-02-26 Teva Pharma 5-cloro-4-hidroxi-1-metil-2-oxo-n-fenil-1,2-dihidroquinolina-3-ca rboxamida, sales y usos de la misma.
EP2597954A4 (en) 2010-07-09 2014-01-01 Teva Pharma DEUTERATED N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOCHINOLINE-3-CARBOXAMIDE, SALT THEREOF AND APPLICATIONS THEREOF

Also Published As

Publication number Publication date
KR20090017694A (ko) 2009-02-18
ES2377149T3 (es) 2012-03-22
DK2035001T3 (da) 2012-02-27
PT2035001E (pt) 2012-02-06
IL195724A0 (en) 2009-09-01
TW200815006A (en) 2008-04-01
HK1121971A1 (en) 2009-05-08
EP2035001A4 (en) 2009-09-23
CN101466379A (zh) 2009-06-24
NZ573846A (en) 2012-01-12
PL2035001T3 (pl) 2012-05-31
EA200870599A1 (ru) 2009-06-30
EP2035001A2 (en) 2009-03-18
TWI400073B (zh) 2013-07-01
US8383645B2 (en) 2013-02-26
KR101495327B1 (ko) 2015-02-24
US7989473B2 (en) 2011-08-02
US20110251235A1 (en) 2011-10-13
JP5226678B2 (ja) 2013-07-03
US20070293537A1 (en) 2007-12-20
ATE532515T1 (de) 2011-11-15
AU2007258366A1 (en) 2007-12-21
NO342485B1 (no) 2018-05-28
IL195724A (en) 2015-09-24
CN101466379B (zh) 2012-10-31
CY1113003T1 (el) 2016-04-13
CA2654982A1 (en) 2007-12-21
BRPI0713694A2 (pt) 2012-10-30
KR20160013273A (ko) 2016-02-03
WO2007146248A2 (en) 2007-12-21
MX2008015808A (es) 2009-02-17
RS52169B (en) 2012-08-31
EP2035001B1 (en) 2011-11-09
UA96449C2 (en) 2011-11-10
SI2035001T1 (sl) 2012-03-30
CA2899472C (en) 2019-04-30
ZA200810790B (en) 2010-03-31
WO2007146248A3 (en) 2008-12-24
HRP20120093T1 (hr) 2012-03-31
US20120302600A1 (en) 2012-11-29
KR20150065951A (ko) 2015-06-15
CA2654982C (en) 2015-11-10
AU2007258366B2 (en) 2012-10-25
AR061348A1 (es) 2008-08-20
JP2009539984A (ja) 2009-11-19
CA2899472A1 (en) 2007-12-21
EA018031B1 (ru) 2013-05-30
KR20140091778A (ko) 2014-07-22

Similar Documents

Publication Publication Date Title
NO20090175L (no) Stabile laquinimod sammensetninger
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
NO20090295L (no) Substituerte heteroarylderivater
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
EA200970156A1 (ru) Пиридизиноновые производные
WO2009024611A3 (en) 4-benzylaminoquinolines, pharmaceutical compositions containing them and their use
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
NO20091395L (no) Nye tiofenderivater
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
ATE528989T1 (de) Kristalline feste rasagilin-base
EA200870217A1 (ru) 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
ATE447568T1 (de) Neue pyrinderivate
EA201070786A1 (ru) Бензофуропиримидиноны
NO20090313L (no) Derivater og analoger av N-etylkinoloner og N-etylazakinoloner
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
PT2310356E (pt) Derivados de adamantildiamida e a sua utilização
MX2009011578A (es) 6-fenilpirimidinonas como moduladores de pim.
EA200900135A1 (ru) Производные пиразола в качестве ингибиторов цитохрома р450
EA200702589A1 (ru) 2,6-хинолинильные производные, способы их получения и их применение
EA201401193A1 (ru) Триарильные соединения и композиции, их содержащие
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
HN2008001393A (es) Derivados de 1,2,4,5- tetrahidro -3h- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
BRPI0518904A2 (pt) formulaÇÕes de nepafenac tàpicas
SG158091A1 (en) Imidazoazepinone compounds

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees